Follistatins in glucose regulation in healthy and obese individuals.

ABSTRACT:

Aims

It has been suggested recently that follistatin (FST) and its homologous protein, follistatin-like 3 (FSTL3), may be a therapeutic target in the treatment of type 2 diabetes because of their glucose-regulatory effects in rodents.

Materials and methods

We investigated this hypothesis in humans by studying the physiology of a possible glycaemia-follistatin feedback loop, that is, whether glucose, but not lipid intake (oral or intravenous), can regulate circulating FST and FSTL3 in healthy humans (n = 32), whether the levels of follistatins change in response to various types of bariatric operation in morbidly obese individuals, with or without type 2 diabetes (n = 41), and whether such changes are associated prospectively with improvement of glucose homeostasis/insulin se

SUBMITTER: Perakakis N 

PROVIDER: S-EPMC6368471 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature